COMMUNIQUÉS West-GlobeNewswire

Spur Therapeutics Announces First Patient Dosed in GALILEO-3 Pivotal Clinical Trial of FLT201 for the Treatment of Gaucher Disease Type 1
07/07/2026
Completion of enrollment anticipated within 12 months GALILEO-3 is intended to support the registration of FLT201 in the adult GD1 population LONDON, July 07, 2026 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced [...]
Luxe Treatment Center marks five years of addiction treatment in Las Vegas, surpassing 1,000 patients served
07/07/2026
Milestone arrives as Nevada remains one of the few states where overdose deaths continue to climb against the national trend. Las Vegas, NV, July 07, 2026 (GLOBE NEWSWIRE) -- Luxe Treatment Center, a licensed addiction [...]
Cynet Joins Pax8 Marketplace to Help MSPs Manage the Modern Attack Path
07/07/2026
Availability on Pax8 makes it easy for MSPs to purchase Cynet alongside the technology they use to run their business BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Cynet , the leader in attack path management, announced the [...]
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
07/07/2026
Company also advances U.S. regulatory pathway for ONP-002 with FDA Type B meeting request All three Australian Phase IIa trial sites — Mackay Base Hospital, Alfred Health, and Royal Adelaide Hospital — are now active [...]
Clinical Excellence in Continuity of Care: Counterpart Assistant (CA) Use Associated With Stronger Performance Across Transitions of Care Measures and Post-Hospitalization Follow-Up
07/07/2026
CA-enabled PCPs showed better HEDIS® post-acute performance, including 33% higher discharge information receipt and an 11% higher rate of post-discharge medication reconciliation, underscoring the role of AI-enabled [...]
SPRINT® PNS Publication Highlights Sustained Benefits in Low Back Pain Patients
07/07/2026
CLEVELAND, July 07, 2026 (GLOBE NEWSWIRE) -- SPR announced the publication of long-term data in the journal Pain and Therapy from a cross-sectional follow-up survey of real-world patients (n=602) with chronic low back [...]
Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research
07/07/2026
eMTBR-Tau offers a non-invasive, blood-based measurement of the tau tangle burden, the core pathology associated with disease progression and cognitive decline in Alzheimer’s disease Immunoassay for eMTBR-Tau is [...]
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
07/07/2026
MIAMI, July 07, 2026 (GLOBE NEWSWIRE) -- Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical [...]
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
07/07/2026
MIAMI, FL, July 07, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory [...]
Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd
07/07/2026
Sets out Shared Intent to Support Delivery of Propanc’s First-In-Human Clinical Trial for PRP MELBOURNE, Australia, July 07, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), [...]
WELL Health Announces Proposed TSXV Listing and Concurrent Financing for WELLSTAR, One of Canada’s Leading Healthcare Software and AI Platforms
07/07/2026
Not for distribution to United States news wire services or for dissemination in the United States. WELLSTAR is expected to become a publicly listed company through a TSXV listing, supported by a Concurrent Financing [...]
Privia Health to Report Second Quarter 2026 Results on Thursday, August 6
07/07/2026
ARLINGTON, Va., July 07, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its second-quarter and six-month periods ended June 30, 2026 [...]
Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI
07/07/2026
Vancouver, Canada, July 07, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, [...]
HMNC Brain Health Announces Publication of Ketabon (KET01) Clinical Trial Results in JAMA Network Open
07/07/2026
Oral prolonged-release ketamine formulation (KET01) demonstrates minimal dissociation and cardiovascular effects with early antidepressant efficacy signals in treatment-resistant depression Results support further [...]
Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535
07/07/2026
In Phase 3 trial in obesity/overweight in China, HRS-7535 achieved a mean weight loss of up to 10.9% at Week 44 and a mean weight loss of up to 11.1% at Week 50 Kailera currently conducting global Phase 2 trial of KAI- [...]
Endogenex Announces Full Enrollment of the ReCET Clinical Study
07/07/2026
350 Patients Enrolled Across Sites in the United States and Australia, Advancing the Path to FDA Approval of a Novel Endoscopic Treatment for Type 2 Diabetes MINNEAPOLIS, July 07, 2026 (GLOBE NEWSWIRE) -- Endogenex, a [...]
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
07/07/2026
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC ® 2026 Lausanne, Switzerland, July 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering [...]
OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium
07/07/2026
LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
07/07/2026
The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHD NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company [...]

Pages